title: Glucagon-like peptide-1: modulator of β-cell dysfunction and death.
abstract: Glucagon-like peptide-1 (GLP-1) is one of the hormones responsible for the incretin effect, a term that refers to the observation that orally administered glucose results in a larger increase in plasma insulin levels and insulin-dependent decrease in blood glucose concentration when compared to the same amount of glucose given intravenously. GLP-1 is secreted mainly by gut endocrine L-cells and is released under the control of carbohydrates, proteins and lipids. Upon secretion, GLP-1 targets different cell types and exerts a wide variety of actions such as potentiation of glucose-stimulated insulin secretion, reduction of appetite, delay of gastric emptying and increase in β-cell mass. These beneficial effects have resulted in the application of GLP-1-based therapies in patients with type 2 diabetes, but also exploitation of its effects in type 1 diabetes is being envisaged. In this review, we focus on the different, short- and long-term action mechanisms of GLP-1 with specific emphasis on its role as a modulator of β-cell function and survival.
authors.affiliation: Laboratory for Clinical and Experimental Endocrinology, 3000, Leuven, Belgium.
authors.forename: D
authors.initials: D
authors.lastname: Rondas
authors.forename: W
authors.initials: W
authors.lastname: D'Hertog
authors.forename: L
authors.initials: L
authors.lastname: Overbergh
authors.forename: C
authors.initials: C
authors.lastname: Mathieu
mesh_terms: D000818:Animals; D016923:Cell Death / Q000187:drug effects; D003920:Diabetes Mellitus / Q000503:physiopathology*; D052216:Glucagon-Like Peptide 1 / Q000494:pharmacology* / Q000502:physiology; D006801:Humans; D050417:Insulin-Secreting Cells / Q000187:drug effects* / Q000502:physiology*
chemical_list: D052216:Glucagon-Like Peptide 1
keywords: GLP-1; glucose-stimulated insulin secretion; incretin-based therapies; type 1 diabetes; type 2 diabetes; β-cell mass